Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1569 ARTÍCULOS , VIENDO DEL 1471 AL 1485

Alzheimer's Disease and Parkinson's Disease: A Review of Current Treatment Adopting a Nanotechnology Approach

Trompetero A, Gordillo A, Del Pilar MC, Cristina VM, Bustos Cruz RH.

Curr Pharm Des. 2018;24(1):22-45. doi: 10.2174/1381612823666170828133059.

Common molecular pathogenesis of disease-related intrinsically disordered proteins revealed by NMR analysis

Shigemitsu Y, Hiroaki H.

J Biochem. 2018 Jan 1;163(1):11-18. doi: 10.1093/jb/mvx056.

Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia: A Randomized Clinical Trial

Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, Hyam J, Oswal A, Day B, Mancini L, Thornton J, Yousry T, Limousin P, Hariz M, Jahanshahi M, Foltynie T.

JAMA Neurol. 2018 Feb 1;75(2):169-178. doi: 10.1001/jamaneurol.2017.3762.

A refined concept: α-synuclein dysregulation disease

Mochizuki H, Choong CJ, Masliah E.

Neurochem Int. 2018 Oct;119:84-96. doi: 10.1016/j.neuint.2017.12.011. Epub 2018 Jan 2.

Neuropathology correlates of cognitive assessments

Brett FM, Kearney H.

Ir J Med Sci. 2018 Aug;187(3):835-844. doi: 10.1007/s11845-017-1733-6. Epub 2018 Jan 18.

Mutation Screening of the CHCHD2 Gene for Alzheimer's Disease and Frontotemporal Dementia in Chinese Mainland Population

Che XQ, Zhao QH, Huang Y, Li X, Ren RJ, Chen SD, Guo QH, Wang G.

J Alzheimers Dis. 2018;61(4):1283-1288. doi: 10.3233/JAD-170692.

Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study

Malek N, Weil RS, Bresner C, Lawton MA, Grosset KA, Tan M, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Wood NW, Ben-Shlomo Y, Williams NW, Grosset DG, Morris HR; PRoBaND clinical consortium.

J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):702-709. doi: 10.1136/jnnp-2017-317348. Epub 2018 Jan 29.

Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models

Hölscher C.

Neuropharmacology. 2018 Jul 1;136(Pt B):251-259. doi: 10.1016/j.neuropharm.2018.01.040. Epub 2018 Jan 31.

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S; ADP Investigators.

Lancet Neurol. 2018 Mar;17(3):213-222. doi: 10.1016/S1474-4422(18)30039-5.

Shedding light on aberrant interactions - a review of modern tools for studying protein aggregates

Kundel F, Tosatto L, Whiten DR, Wirthensohn DC, Horrocks MH, Klenerman D.

FEBS J. 2018 Oct;285(19):3604-3630. doi: 10.1111/febs.14409. Epub 2018 Mar 4.

Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives

Baker DJ, Petersen RC.

J Clin Invest. 2018 Apr 2;128(4):1208-1216. doi: 10.1172/JCI95145. Epub 2018 Feb 19.

Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers

Tonda-Turo C, Origlia N, Mattu C, Accorroni A, Chiono V.

Curr Med Chem. 2018;25(41):5755-5771. doi: 10.2174/0929867325666180221125759.

Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease

Weinshenker D.

Trends Neurosci. 2018 Apr;41(4):211-223. doi: 10.1016/j.tins.2018.01.010. Epub 2018 Feb 20.

Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases

Kreutzer AG, Nowick JS.

Acc Chem Res. 2018 Mar 20;51(3):706-718. doi: 10.1021/acs.accounts.7b00554. Epub 2018 Mar 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias